Clinical trial · Observational
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions
Dermoscopy Evaluation of Pigmented Skin Lesions by a Neuronal Network Clinical Decision Support: an Open Prospective Non Interventional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016). The golden standard, dermoscopy, enables Dermatologists to diagnose with a sensitivity of 40%, and a 8-12% specificity, approximately. Additional diagnostic abilities are restricted to devices which are either unproved or experimental. A new technology of Neuronal Network Clinical Decision Support (NNCD) was developed. It uses a dermoscopic imaging device and a camera able to capture an image. The photo is transferred to a Cloud Server and further analyzed by a trained classifier. Classifier training is aimed at a high accuracy diagnosis of Dysplastic Nevi (DN), Spitz Nevi and Malignant Melanoma detection with assistance from a Deep Neuronal Learning network (DLN). Diagnosis output is an excise or do not excise recommendation for pigmented skin lesions. A total of 80 subjects already referred to biopsy pigmented skin lesions will be examined by dermoscopy imaging in a non interventional study. Artificial Intelligence output results, as measured by 2 different dermoscopes, to be compared to ground truth biopsies, by either classifier decisions or a novel Modified Classifier Technology output decisions. Primary endpoints are sensitivity and specificity detection of the NNCD techniques. Secondary endpoints are the positive and negative prediction ratios of NNCD techniques.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dysplastic Nevi | Cutaneous Dysplastic Nevus | ALIAS | 0.90 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Pigmented Skin Lesion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dermoscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Dermoscopy
- description
- Dermoscopic imaging of a lesion decided to be biopsied
- interventionNames
- Device: dermoscopy
Primary outcomes (2)
- measure
- Sensitivity for Classifier results as compared to biopsy
- timeFrame
- 15 months
- description
- A Sensitivity of at least 75% for Classifier results as compared to biopsy
- measure
- Sensitivity for MCT results as compared to biopsy
- timeFrame
- 15 months
- description
- A Sensitivity of at least 85% for Classifier results as compared to biopsy
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged 18-90 years * A pigmented lesion by dermoscopy. * Clinical management by the examining dermatologist results in biopsy * The diameter of the pigmented area is between 1 and 40 millimeters * The patient has consented to participate in the study and has signed the Informed Consent Form Exclusion Criteria: * Non intact skin (ulcers, bleeding) * The lesion is located within 1 cm of the eye * The lesion is located on mucosal surfaces * The lesion is on or under nails
References
Publications (8)
- BACKGROUNDEggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014 Mar 1;383(9919):816-27. doi: 10.1016/S0140-6736(13)60802-8. Epub 2013 Sep 19. PMID 24054424
- BACKGROUNDMayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology. J Am Acad Dermatol. 2014 Oct;71(4):599.e1-599.e12; quiz 610, 599.e12. doi: 10.1016/j.jaad.2014.05.046. PMID 25219716
- BACKGROUNDSiegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4. PMID 22237781
- BACKGROUNDNoor O 2nd, Nanda A, Rao BK. A dermoscopy survey to assess who is using it and why it is or is not being used. Int J Dermatol. 2009 Sep;48(9):951-2. doi: 10.1111/j.1365-4632.2009.04095.x. PMID 19702978
- BACKGROUNDAmerican Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma; Tsao H, Olazagasti JM, Cordoro KM, Brewer JD, Taylor SC, Bordeaux JS, Chren MM, Sober AJ, Tegeler C, Bhushan R, Begolka WS. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol. 2015 Apr;72(4):717-23. doi: 10.1016/j.jaad.2015.01.025. Epub 2015 Feb 16. PMID 25698455
- BACKGROUNDCampos-do-Carmo G, Ramos-e-Silva M. Dermoscopy: basic concepts. Int J Dermatol. 2008 Jul;47(7):712-9. doi: 10.1111/j.1365-4632.2008.03556.x. PMID 18613881
- DERIVEDDascalu A, David EO. Skin cancer detection by deep learning and sound analysis algorithms: A prospective clinical study of an elementary dermoscope. EBioMedicine. 2019 May;43:107-113. doi: 10.1016/j.ebiom.2019.04.055. Epub 2019 May 14. PMID 31101596